Factory supply Bazedoxifene acetate Cas 198481-33-3 with high quality and best price

Details:

Bazedoxifene Acetate is a selective estrogen receptor modulator (SERM) used primarily for the prevention and treatment of osteoporosis in postmenopausal women. Below is a structured overview of its key features:

1. Mechanism of Action

• SERM Activity:

  • Agonist in bone: Maintains bone density by mimicking estrogen's protective effects on bone resorption.

  • Antagonist in breast and uterine tissues: Blocks estrogen activity, reducing risks of breast/endometrial cancer.

2. Indications

Osteoporosis Prevention/Treatment: Reduces fracture risk in postmenopausal women.

Combination Therapy: Paired with conjugated estrogens (e.g., Duavee®) to treat moderate-to-severe menopausal vasomotor symptoms (hot flashes) while protecting against osteoporosis.

3. Dosage & Administration

Standard Dose: 20 mg orally once daily (alone or in combination).

Timing: Can be taken with or without food.

Duration: Long-term use under medical supervision.

4. Side Effects

Common: Hot flashes, leg cramps, sweating, gastrointestinal discomfort.

• Serious:

  • Venous Thromboembolism (e.g., DVT, pulmonary embolism).

  • Increased risk of stroke in certain populations.

  • Rare cases of allergic reactions (rash, angioedema).

5. Contraindications

History of venous thromboembolism or active clotting disorders.

Undiagnosed abnormal uterine bleeding.

Pregnancy or breastfeeding (estrogen antagonism may harm fetal development).

Severe hepatic impairment.

6. Drug Interactions

Warfarin: May alter anticoagulant effects (monitor INR).

Cholestyramine: Reduces absorption (separate doses by ≥2 hours).

Strong CYP3A4 Inducers (e.g., rifampin): May decrease efficacy.

7. Advantages Over Other SERMs

Lower risk of endometrial hyperplasia compared to unopposed estrogen therapy.

Combined formulations (e.g., with estrogen) address both menopausal symptoms and bone health.

8. Safety Monitoring

Regular bone density scans (DEXA).

Watch for signs of thrombosis (leg pain, shortness of breath).

Assess liver function in long-term users.

9. Research & Development

Investigated for breast cancer prevention in high-risk postmenopausal women.

Ongoing studies on its role in cardiovascular health (mixed evidence).

Summary

Bazedoxifene acetate offers dual benefits for postmenopausal women by preserving bone density and mitigating estrogen-related risks. Its combination with conjugated estrogens (e.g., Duavee®) uniquely addresses both osteoporosis and vasomotor symptoms. However, thromboembolic risks necessitate careful patient selection and monitoring. It represents a tailored approach to menopausal management, balancing efficacy with safety.